Treatment: symptomatic treatment of hypoglycaemia

Ann Endocrinol (Paris). 2013 Jul;74(3):196-9. doi: 10.1016/j.ando.2013.05.009. Epub 2013 Jun 18.
No abstract available

Publication types

  • Consensus Development Conference
  • Practice Guideline

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Blood Glucose / drug effects
  • Blood Glucose / physiology
  • Diazoxide / therapeutic use
  • Everolimus
  • Humans
  • Hypoglycemia / etiology
  • Hypoglycemia / therapy*
  • Insulinoma / complications
  • Insulinoma / drug therapy
  • Octreotide / therapeutic use
  • Pancreatic Neoplasms / complications
  • Pancreatic Neoplasms / drug therapy
  • Protein Kinase Inhibitors / therapeutic use
  • Signal Transduction / physiology
  • Sirolimus / analogs & derivatives
  • Sirolimus / therapeutic use
  • Somatostatin / analogs & derivatives
  • Somatostatin / therapeutic use
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • TOR Serine-Threonine Kinases / physiology

Substances

  • Antineoplastic Agents
  • Blood Glucose
  • Protein Kinase Inhibitors
  • Somatostatin
  • Everolimus
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Diazoxide
  • Octreotide
  • Sirolimus